Original Research
Published on 15 May 2023
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
- 21,566 views
- 27 citations